Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Vizamyl

tijana being interviewed

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

- PMLiVE

Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

The company is seeking approval of donanemab to treat patients with early stages of the disease

- PMLiVE

FDA approves Geron’s Rytelo to treat lower-risk myelodysplastic syndrome patients

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

- PMLiVE

Alzheimer’s Research UK awards Scottish universities £100,000 for dementia research

The neurological condition affects more than 944,000 people in the UK

Biogen Idec building

Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer’s drug

The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

Study reveals two copies of APOE4 gene could increase risk of developing Alzheimer’s

The progressive neurodegenerative disease is the most common form of dementia

- PMLiVE

Eisai and BioArctic sign research evaluation agreement for potential new Alzheimer’s treatment

AD is the most common form of dementia, which affects around 55 million people globally

- PMLiVE

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links